NEW YORK (GenomeWeb) — CRISPR-based therapeutics developer Editas Medicine has agreed to provide up to $125 million in research funding to the Broad Institute in exchange for the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.